Maxine Gowen Purchases 4,102 Shares of Idera Pharmaceuticals Inc. (IDRA) Stock
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) Director Maxine Gowen purchased 4,102 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were bought at an average price of $2.56 per share, for a total transaction of $10,501.12. Following the acquisition, the director now directly owns 10,543 shares in the company, valued at approximately $26,990.08. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) opened at 2.18 on Friday. The company’s market cap is $264.60 million. The firm has a 50-day moving average price of $2.20 and a 200 day moving average price of $1.82. Idera Pharmaceuticals Inc. has a 12 month low of $1.19 and a 12 month high of $4.42.
Idera Pharmaceuticals (NASDAQ:IDRA) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.11) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.11). Idera Pharmaceuticals had a negative return on equity of 64.09% and a negative net margin of 6,169.32%. Equities research analysts predict that Idera Pharmaceuticals Inc. will post ($0.45) EPS for the current year.
A number of large investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Idera Pharmaceuticals by 10.7% in the second quarter. State Street Corp now owns 1,332,201 shares of the company’s stock worth $2,041,000 after buying an additional 129,033 shares in the last quarter. Rhumbline Advisers increased its stake in Idera Pharmaceuticals by 1.0% in the second quarter. Rhumbline Advisers now owns 88,364 shares of the company’s stock worth $135,000 after buying an additional 860 shares in the last quarter. Alliancebernstein L.P. increased its stake in Idera Pharmaceuticals by 19.8% in the second quarter. Alliancebernstein L.P. now owns 66,600 shares of the company’s stock worth $102,000 after buying an additional 11,000 shares in the last quarter. BlackRock Fund Advisors increased its stake in Idera Pharmaceuticals by 4.3% in the second quarter. BlackRock Fund Advisors now owns 2,332,615 shares of the company’s stock worth $3,569,000 after buying an additional 97,125 shares in the last quarter. Finally, BlackRock Investment Management LLC increased its stake in Idera Pharmaceuticals by 7.3% in the second quarter. BlackRock Investment Management LLC now owns 334,389 shares of the company’s stock worth $512,000 after buying an additional 22,791 shares in the last quarter. Institutional investors own 28.44% of the company’s stock.
Several analysts recently weighed in on IDRA shares. Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Idera Pharmaceuticals in a report on Monday, September 26th. Zacks Investment Research lowered Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 4th.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Stock Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.